EC Number   |
Application |
Reference |
|---|
    3.1.3.25 | drug development |
the enzyme is a target for development of lithium-mimetic agents for the treatment of bipolar disorder, high-throughput cell-based screening using scintillation proximity assay for the discovery of enzyme inhibitors, overview |
665758 |
| 3.1.3.25 | medicine |
a homozygous variant consisting of a 5-bp duplication leads to a frameshift and a premature stop codon (p.Ser165Trpfs*10) that cosegregates with the disease of intellectual disability in 26 genotyped family members |
751618 |
| 3.1.3.25 | pharmacology |
the enzyme is the putative target of lithium therapy |
663506 |
| 3.1.3.25 | synthesis |
construction of a pathway to produce inositol from glucose using polyphosphate glucokinase PPGK from Arthrobacter sp. OY3WO11, inositol 1-phosphate synthase IPS from Trypanosoma brucei TREU927 and inositol monophosphatase IMP Escherichia coli, all expressed in Escherichia coli. The conversion ratio from glucose to inositol reaches 90% |
747666 |
| 3.1.3.25 | synthesis |
production of myo-inositol from glucose by a novel trienzymatic cascade of polyphosphate glucokinase, inositol 1-phosphate synthase and inositol monophosphatase. myo-Inositol (inositol) is important in the cosmetics, pharmaceutical and functional food industries. The conversion ratio from glucose to inositol reaches 90%, which is promising for the enzymatic synthesis of inositol without ATP supplementation |
747666 |
